Structural-based Study to Identify the Repurposed Candidates against Bacterial Infections
Authors:
- 1 June 2025
- journal article
- research article
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 32 (18) , 3693-3718
Abstract
Background: Microbial infections are mostly caused by Gram-positive as well as Gram-negative bacteria affecting millions of people worldwide. There is an urgent need to explore existing molecules or discover new chemical entities (NCEs) against bacterial infection. Objective: The main objective of the current investigation is to explore recently US-FDA- approved drugs (2019-2023) against various targets of Gram-positive and Gram-negative bacteria using high-performance computational studies. Aim: The current study aims to find out the potential drugs of recently US-FDA-approved drugs as repurposing candidates against bacterial infections. Methods: The targets of Gram-positive and Gram-negative bacteria were identified using literature studies whereas ligands were selected from the FDA-approved drug lists of the last 5 years. Further, the drugs and targets were prepared through the LigPrep and Protein Preparation Wizard modules of Schrödinger (release 2023-1) respectively. The GlideDock and Desmond modules of Schrödinger were used for the molecular docking study and molecular dynamics simulation respectively. Results: A total of 202 drugs were found in the FDA lists which were approved in the last five years. Out of them, 77 drugs were selected for docking study based on their properties. A total of 21 drugs have shown energetically favored binding conformation of drugs in the active site of bacterial targets. The interaction of these drugs was studied in detail using molecular dynamics (MD) simulation. The MD simulation results have shown stable dynamic conformation of triclabendazole (anti-helminthic) with topoisomerase II of gram-negative bacteria whereas solriamfetol (for obstructive sleep apnea) has shown stable dynamic conformation in the active site of restriction endonuclease of gram-positive bacteria. Conclusion: The identified drugs can be repurposed against Gram-positive and Gramnegative bacterial infections. However, further experimental studies are required to confirm their antibacterial potential.Keywords
Funding Information
- Department of Science and Technology, Science and Engineering Research Board (DST-SERB), Govt of India (SRG/2022/000011)
This publication has 60 references indexed in Scilit:
- In silico drug repurposing in COVID-19: A network-based analysisBiomedicine & Pharmacotherapy, 2021
- Repurposing of FDA‐approved drugs against active site and potential allosteric drug‐binding sites of COVID‐19 main proteaseProteins: Structure, Function, and Bioinformatics, 2021
- Alternative strategies for the application of aminoglycoside antibiotics against the biofilm-forming human pathogenic bacteriaApplied Microbiology and Biotechnology, 2020
- Antibiotics resistance mechanism2020
- In silico approaches and tools for the prediction of drug metabolism and fate: A reviewComputers in Biology and Medicine, 2019
- Performing an In Silico Repurposing of Existing Drugs by Combining Virtual Screening and Molecular Dynamics Simulation2018
- Docking techniques in pharmacology: How much promising?Computational Biology and Chemistry, 2018
- Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichmentsJournal of Computer-Aided Molecular Design, 2013
- The environment of amide groups in protein–ligand complexes: H-bonds and beyondJournal of Molecular Modeling, 2005
- What role do surfaces play in GB models? A new‐generation of surface‐generalized born model based on a novel gaussian surface for biomoleculesJournal of Computational Chemistry, 2005